Bioqual, Inc. (BIOQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bioqual, Inc. (BIOQ) trades at $32.50 with AI Score 38/100 (Grade D). Bioqual, Inc. is a preclinical research services company focused on infectious diseases and animal research models. It serves commercial and government clients in the United States. Market cap: $29.07M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BIOQ: BIOQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIOQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BIOQ: 1/1 perspectives are bearish.
How is this calculated? →Bioqual, Inc. (BIOQ) Healthcare & Pipeline Overview
Bioqual, Inc., founded in 1981, provides pre-clinical research services, focusing on in-vivo and in-vitro studies for infectious diseases like COVID-19 and AIDS. Serving both commercial and government clients in the U.S., the company offers specialized assays and animal research models, operating with a market capitalization of $29.07M.
What Is the Investment Thesis for BIOQ?
Bioqual, Inc. presents a focused investment opportunity within the preclinical research services sector. The company's specialization in infectious diseases, including COVID-19 and AIDS, positions it to capitalize on ongoing research and development efforts in these areas. With a market capitalization of $29.07M and a P/E ratio of 72.91, the company's valuation reflects its growth potential. Key value drivers include continued government and commercial research funding for infectious diseases and expansion of its service offerings. Potential risks include the company's low profit margin of 1.0% and negative gross margin of -0.7%, indicating operational inefficiencies. Investors should monitor the company's ability to improve profitability and capitalize on growth opportunities in the preclinical research market.
Based on FMP financials and quantitative analysis
BIOQ Key Highlights
- Market capitalization of $29.07M, reflecting its small-cap status within the healthcare sector.
- P/E ratio of 72.91, indicating a relatively high valuation compared to earnings.
- Profit margin of 1.0%, suggesting limited profitability and potential operational challenges.
- Gross margin of -0.7%, indicating that the cost of services exceeds revenue generated.
- Beta of -0.07, suggesting low volatility relative to the market.
Who Are BIOQ's Competitors?
BIOQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127.35M | 53 |
| MDDVF Medical Developments International Limited | $0.30 | -17.89% | $34.23M | 48 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIOQ's Key Strengths?
- Specialization in infectious disease research.
- Established relationships with government clients.
- Expertise in in-vivo and in-vitro studies.
- Proprietary animal research models.
What Are BIOQ's Weaknesses?
- Low profit margin.
- Negative gross margin.
- Small market capitalization.
- Limited geographic reach.
What Could Drive BIOQ Stock Higher?
- Continued government funding for COVID-19 and infectious disease research.
- Potential partnerships with pharmaceutical companies for drug development programs.
- Development and commercialization of new animal research models.
- Expansion of service offerings in response to emerging infectious diseases.
- Investment in advanced technologies to enhance research capabilities.
What Are the Key Risks for BIOQ?
- Negative return on equity (-3.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Changes in government research funding priorities.
- Intense competition from larger research organizations.
- Economic downturn affecting research budgets.
- Regulatory changes impacting preclinical research.
- Low profit margin and negative gross margin.
What Are the Growth Opportunities for BIOQ?
- Expansion of COVID-19 Research Services: The ongoing COVID-19 pandemic continues to drive demand for research services related to vaccine and therapeutic development. Bioqual can leverage its expertise in virology and immunology to expand its service offerings in this area. The global market for COVID-19 research is expected to remain robust in the coming years, providing Bioqual with a significant growth opportunity. Timeline: Ongoing.
- Development of New Animal Research Models: Bioqual can develop and commercialize new animal research models for infectious diseases, addressing a critical need in preclinical research. The market for animal research models is estimated to be worth billions of dollars annually, with a growing demand for specialized models that accurately mimic human disease. Timeline: 2-3 years.
- Geographic Expansion: Bioqual can expand its geographic reach by establishing partnerships with research institutions and pharmaceutical companies in new markets. The global market for preclinical research services is growing rapidly, particularly in emerging economies with increasing healthcare investments. Timeline: 3-5 years.
- Strategic Partnerships with Pharmaceutical Companies: Bioqual can form strategic partnerships with pharmaceutical companies to provide preclinical research services for drug development programs. These partnerships can provide Bioqual with a stable source of revenue and access to new technologies and expertise. Timeline: Ongoing.
- Investment in Advanced Technologies: Bioqual can invest in advanced technologies, such as genomics and proteomics, to enhance its research capabilities and offer new services to clients. These technologies can enable Bioqual to provide more comprehensive and sophisticated research solutions, differentiating it from competitors. Timeline: 1-2 years.
What Opportunities Does BIOQ Have?
- Expansion of COVID-19 research services.
- Development of new animal research models.
- Geographic expansion into new markets.
- Strategic partnerships with pharmaceutical companies.
What Threats Does BIOQ Face?
- Intense competition from larger research organizations.
- Changes in government research funding priorities.
- Economic downturn affecting research budgets.
- Regulatory changes impacting preclinical research.
What Are BIOQ's Competitive Advantages?
- Specialization in infectious disease research provides a niche market.
- Long-standing relationships with government and commercial clients.
- Expertise in both in-vivo and in-vitro preclinical research.
- Proprietary animal research models.
What Does BIOQ Do?
Founded in 1981, Bioqual, Inc. is a preclinical research services company providing in-vivo and in-vitro research to commercial and government clients within the United States. The company specializes in research services for a range of infectious diseases, including COVID-19, AIDS, influenza, RSV infection, and flavivirus infections such as Zika and Dengue. Bioqual also conducts research on malaria, hepatitis, and cancer. Bioqual's service offerings include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition to its assay services, Bioqual provides animal research model-related services. Headquartered in Rockville, Maryland, Bioqual operates with 278 employees and serves as a critical partner for organizations requiring preclinical research in infectious diseases and related fields. The company's expertise in both in-vivo and in-vitro studies allows it to offer comprehensive research solutions, supporting the development of new therapies and vaccines.
What Products and Services Does BIOQ Offer?
- Provides in-vivo preclinical research services.
- Offers in-vitro preclinical research services.
- Conducts research on infectious diseases such as COVID-19 and AIDS.
- Performs sample processing and virus stock generation.
- Offers virus neutralization and hemagglutination inhibition assays.
- Provides quantitative PCR and ELISA detection assays.
- Conducts flow cytometry and lymphocyte proliferation assays.
- Provides animal research model related services.
How Does BIOQ Make Money?
- Generates revenue by providing preclinical research services to commercial clients.
- Generates revenue by providing preclinical research services to government clients.
- Revenue is derived from in-vivo and in-vitro research studies.
- Revenue is earned from specialized assays and animal research models.
What Industry Does BIOQ Operate In?
Bioqual, Inc. operates within the medical diagnostics and research industry, a segment driven by ongoing advancements in healthcare and increasing demand for preclinical research services. The industry is characterized by intense competition, with companies vying for government and commercial research contracts. Market trends include a growing focus on infectious disease research, driven by global health concerns and the need for new therapies and vaccines. Bioqual's specialization in infectious diseases positions it to capitalize on these trends, although it faces competition from larger and more established players in the market.
Who Are BIOQ's Key Customers?
- Commercial pharmaceutical companies.
- Government research institutions.
- Biotechnology companies.
- Academic research centers.
F-Score 3/9Financial Health
Bioqual, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.86 places it in the grey zone, a middle ground that warrants monitoring.
Quarterly Financial Performance: Bioqual, Inc.
Revenue for Bioqual, Inc. came in at $9.8M during Q1 2026, a 10.3% contraction versus the preceding quarter. The company recorded a net loss of $753K, with diluted EPS of $-0.84. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BIOQ averaged $-0.35 in diluted EPS.
BIOQ Valuation & Market Position
With a $29.07M market cap, Bioqual, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BIOQ's quantitative score of 38/100 is below the peer average of 61/100.
ROE -3%Key Financial Metrics
Return on equity for Bioqual, Inc. stands at -3.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 17.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.3%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Bioqual, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Hanne Andersen-Elyard. BIOQ has traded publicly since 2002.
BIOQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Specialization in infectious disease research.
- Established relationships with government clients.
- Expertise in in-vivo and in-vitro studies.
- Proprietary animal research models.
Bear Case
- Low profit margin.
- Negative gross margin.
- Small market capitalization.
- Limited geographic reach.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10M | -$752,524 | -$0.84 |
| Q4 2025 | $11M | -$137,285 | -$0.15 |
| Q3 2025 | $10M | -$248,832 | -$0.28 |
| Q2 2025 | $12M | -$96,657 | -$0.11 |
Based on FMP financials and quantitative analysis
BIOQ Latest News
No recent news available for BIOQ.
BIOQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIOQ.
Price Targets
Wall Street price target analysis for BIOQ.
BIOQ MoonshotScore
What does this score mean?
The MoonshotScore rates BIOQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hanne Andersen-Elyard
CEO
Hanne Andersen-Elyard is the CEO of Bioqual, Inc. Her background includes extensive experience in managing research organizations and leading teams of scientists and researchers. She has a strong track record in strategic planning, business development, and operational management within the healthcare and biotechnology sectors. Her expertise spans preclinical research, drug development, and regulatory affairs. She is responsible for overseeing all aspects of Bioqual's operations and driving the company's growth strategy.
Track Record: Under Hanne Andersen-Elyard's leadership, Bioqual, Inc. has focused on expanding its research capabilities in infectious diseases and strengthening its relationships with government and commercial clients. She has overseen the development of new animal research models and the implementation of advanced technologies to enhance the company's service offerings. Her strategic decisions have contributed to Bioqual's position as a specialized provider of preclinical research services.
BIOQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bioqual, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to significant price volatility.
- Higher potential for fraud or manipulation compared to exchange-listed stocks.
- OTC Other status indicates the company may not meet minimum financial standards.
- Lack of regulatory oversight increases investment risk.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC Other stocks.
- Consult with a financial advisor before investing.
- The company has been in operation since 1981.
- Bioqual has a specialization in infectious disease research.
- The company serves both commercial and government clients.
- Bioqual has 278 employees, suggesting a substantial operation.
- The company's headquarters are in Rockville, Maryland.
What Investors Ask About Bioqual, Inc. (BIOQ) — Healthcare
What does Bioqual, Inc. do?
Bioqual, Inc. specializes in providing preclinical research services to commercial and government clients, focusing on in-vivo and in-vitro studies. The company conducts research on infectious diseases like COVID-19, AIDS, and influenza, offering services such as sample processing, virus stock generation, and various assays. Bioqual also provides animal research model-related services, playing a critical role in supporting the development of new therapies and vaccines for infectious diseases.
What are the main risks for BIOQ?
The main risks for Bioqual, Inc. include its low profit margin and negative gross margin, indicating potential operational inefficiencies. As an OTC Other stock, BIOQ faces risks related to limited liquidity, regulatory oversight, and financial disclosure. Changes in government research funding priorities and intense competition from larger research organizations also pose significant challenges. Economic downturns could affect research budgets, impacting Bioqual's revenue and profitability. Investors should carefully consider these risks before investing in BIOQ.
What are the key factors to evaluate for BIOQ?
Bioqual, Inc. (BIOQ) holds an AI score of 38/100 (low). Not financial advice.
How frequently does BIOQ data refresh on this page?
BIOQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BIOQ's recent stock price performance?
Bioqual, Inc. (BIOQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in infectious disease research. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOQ overvalued or undervalued right now?
Valuing Bioqual, Inc. (BIOQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BIOQ?
Before investing in Bioqual, Inc. (BIOQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BIOQ to a portfolio?
Key strength of Bioqual, Inc. (BIOQ): Specialization in infectious disease research. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry higher risk than exchange-listed stocks.
- AI analysis is pending and may provide further insights.